Literature DB >> 2572531

The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues.

C R De Potter1, S Van Daele, M J Van de Vijver, C Pauwels, G Maertens, J De Boever, D Vandekerckhove, H Roels.   

Abstract

The expression of the neu oncogene product was investigated in invasive and non-invasive ductal carcinomas of the breast, non-neoplastic lesions of the breast, fragments of normal adult and fetal breasts and in several other normal and fetal tissues at different weeks of pregnancy by means of an immunohistochemical study with monoclonal antibodies. The staining pattern along the cytoplasmic membrane was specific for malignancy and occurred in 29% of the breast carcinomas. It was observed in invasive carcinomas as well as in ductal carcinoma in situ and it showed a significantly higher expression in premenopausal women than in postmenopausal women. This higher expression was also present in oestrogen receptor-negative tumours. The tubules of the fetal and adult kidney, the absorption cells of the fetal and adult small and large intestine, the sebaceous glands of the fetal and adult small and large intestine, the sebaceous glands of the fetal and adult skin, the adult endocervix, the endometrium, the C-cells of the thyroid, hepatocytes and all ductal cells of the fetal breast showed a constant diffuse intracytoplasmic granular staining. staining. The same granular intracytoplasmic staining pattern was focally observed in rare cases of normal breast tissue in adults and in some cases of epitheliosis, aprocrine metaplasia and some breast carcinoma cells, which did not express neu oncogene product on their membrane. Western blot experiments showed that the cytoplasmic protein had a molecular weight of 155 kD (kilodaltons); the membrane protein is the known 185 kD neu protein.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572531     DOI: 10.1111/j.1365-2559.1989.tb01587.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  23 in total

1.  Extracting functional information from tissues.

Authors:  M P DiGiovanna
Journal:  Mol Diagn       Date:  2001-03

Review 2.  Molecular analysis of premalignant and carcinoma in situ lesions of the human breast.

Authors:  P S Steeg; S E Clare; J A Lawrence; Q Zhou
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

3.  p185, an immunodominant epitope, is an autoantigen mimotope.

Authors:  Sanjeev Kumar; John A Hinks; Joseph Maman; Chelliah T Ravirajan; Laurence H Pearl; David A Isenberg
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

4.  Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value.

Authors:  Rafael Molina; Jose M Augé; Jose M Escudero; Xavier Filella; Gabriel Zanon; Jaume Pahisa; Blanca Farrus; Montserrat Muñoz; Martin Velasco
Journal:  Tumour Biol       Date:  2010-04-02

5.  The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Chem Rev       Date:  2018-12-27       Impact factor: 60.622

6.  C-erbB-2 immunostaining: problems with interpretation.

Authors:  E W Kay; C J Walsh; M Cassidy; B Curran; M Leader
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

7.  ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.

Authors:  A A Keshgegian
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

Review 8.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 9.  Biological features of premalignant disease in the human breast.

Authors:  D C Allred; S K Mohsin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

10.  Characterization of a monoclonal antibody directed against the epidermal growth factor receptor binding site.

Authors:  R Pellegrini; F Centis; S Martignone; A Mastroianni; E Tagliabue; E Tosi; S Ménard; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.